328 W. Claiborne St.
P.O. Box 964
Monroeville, Alabama 36460
(251) 575-4203
     
Depression: Depression & Related Conditions
Resources
Basic Information
Introduction and Types of Depressive DisordersRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Simple Treatments to Banish Winter BluesMillennials' Odds for Depression Rise With Social Media UseListen Up! Hearing Loss Tied to Late-Life DepressionHealth Tip: Risk Factors for Depression After PregnancyThe Link Between Social Media and DepressionMany Say Ketamine Eased Their Depression, But Is It Safe?Docs Should Screen for Depression During, After PregnancyDepression Is a Risk for Teens, Adults With EpilepsyStimulating One Brain Area May Ease Tough-to-Treat DepressionAnti-Seizure Drug May Be New Weapon Against DepressionMichael Phelps Champions the Fight Against DepressionFacebook Posts May Hint at DepressionDo Dimmer Days in Pregnancy Raise Postpartum Depression Risk?New Dads Can Get the Baby Blues, TooHealth Tip: Help a New Mom With Postpartum DepressionCould a Blood Test Help Spot Severe Depression?Treating Depression May Prevent Repeat Heart AttackSupportive Managers Key When a Worker Is DepressedKnow the Signs of Postpartum DepressionAre Your Meds Making You Depressed?Depression, Money Woes Higher in Heart Patients With Job LossSnubbed on Social Media? Your Depression Risk May RiseNever Ignore DepressionECT Effective for Treatment-Resistant DepressionRates of Major Depression Up Among U.S. Insured, Esp. YouthDepression Striking More Young People Than EverDepression May Dampen MemoryCould Mom-to-Be's Antidepressants Have an Upside for Baby's Brain?Grip Strength Indicative of Cognition in Major DepressionKetamine Nasal Spray Shows Promise Against Depression, SuicideTelltale Clues That Your Child Is DepressedPrenatal Exposure to SSRI Tied to Fetal Brain DevelopmentDepressive Symptoms Tied to Diabetes Self-ManagementMany Grad Students Struggle With Anxiety, DepressionIL-6 Levels Predict Response to ECT in Depressive Disorder1 in 20 Younger Women Suffers Major DepressionHeart-Healthy 'DASH' Diet May Also Help Lower Depression RiskGuidelines Updated for Managing and ID'ing Adolescent DepressionAntidepressants Do Work, Some Better Than Others: StudyTreatment Initiation for Depression Low in Primary CareDuring 2013 to 2016, 8.1 Percent of U.S. Adults Had DepressionDepression Common in U.S., Women Hit HardestNo Proof At-Home 'Cranial Stimulation' Eases DepressionAcne Linked to Increased Risk of Major Depressive DisorderMany With Depression Delay, Avoid TreatmentTalk Therapy May Be Worth It for Teen DepressionPreventive Intervention for Premature Infants Effective
Links
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse

IL-6 Levels Predict Response to ECT in Depressive Disorder


HealthDay News
Updated: Mar 13th 2018

new article illustration

TUESDAY, March 13, 2018 (HealthDay News) -- For patients with major depressive disorder, interleukin-6 (IL-6) may predict benefit from electroconvulsive therapy (ECT), according to a study published recently in the Journal of Clinical Psychiatry.

Jennifer L. Kruse, M.D., from the University of California at Los Angeles, and colleagues examined whether markers of inflammation predicted response to ECT in patients with treatment-resistant depression. Levels of C-reactive protein (CRP), IL-6, IL-8, and tumor necrosis factor α, and severity of depression symptoms (Montgomery-Asberg Depression Rating Scale [MADRS]) were assessed before ECT treatment, after the second ECT session, and at completion of the index treatment series in 29 patients.

The researchers found that there was a correlation for higher IL-6 levels at baseline, but not other inflammatory markers or clinical variables, with lower end-of-treatment MADRS score (P = 0.01). IL-6 remained a significant predictor of end-of treatment MADRS for women (P = 0.02), but not men (P = 0.1), when stratified by sex; CRP was a significant predictor for women (P = 0.04), but not men (P = 0.66). There were increases in CRP and IL-6 from baseline to the second ECT session (P < 0.01); levels returned to baseline at the end of treatment. These changes were not associated with MADRS score over the course of ECT.

"Levels of IL-6 prior to ECT treatment may be useful in identifying those depressed patients most likely to benefit from ECT treatment," the authors write.

Abstract/Full Text (subscription or payment may be required)




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net